Pacira BioSciences, Inc. PCRX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 79.3%+1.7pp | 79.4%+3.7pp | 79.2%+4.8pp | 78.2%+4.1pp | 77.6%+4.5pp | |
| Operating margin | 3.3%— | 2.6%— | —— | —— | —— | |
| Net margin | 0.7%— | 1%— | —— | —— | —— | |
| Returns | ||||||
| Return on equity | 0.7%— | 1%— | —— | —— | —— | |
| Return on invested capital | 2.7%— | 1.9%— | —— | —— | —— | |
| Efficiency | ||||||
| Asset turnover | 0.5×+0.1× | 0.5×+0.1× | 0.5×+0.1× | 0.4×0.0× | 0.4×0.0× | |
| Liquidity | ||||||
| Current ratio | 4.7×+2.3× | 4.5×+2.1× | 5.3×+3.0× | 2.4×-4.4× | 2.4×-3.4× | |
| Leverage | ||||||
| Debt-to-equity | 0.6×+0.2× | 0.6×-0.1× | 0.6×+0.1× | 0.5×+0.3× | 0.4×+0.2× | |
| Net debt / EBITDA | 2.3×— | 2.4×— | —— | —— | —— | |
| Per Share | ||||||
| Book value per share | $15.98-6.9% | $15.39-8.6% | $16.36+0.7% | $16.67-4.2% | $17.16+0.4% | |
| Valuation | ||||||
| Market capitalization | $942.78M-16.0% | $1.11B+28.0% | $1.16B+66.6% | $1.14B-14.3% | $1.15B-15.4% | |
| Price / earnings | 183.5×— | 158.3×— | —— | —— | —— | |
| Price / sales | 1.3×-0.3× | 1.5×+0.3× | 1.6×+0.6× | 1.6×-0.3× | 1.6×-0.4× | |
| Price / book | 1.4×0.0× | 1.6×+0.5× | 1.6×+0.7× | 1.5×0.0× | 1.4×-0.1× | |
| EV / EBITDA | 10.5×— | 12.5×— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Pacira BioSciences, Inc.'s profit margins?
- Pacira BioSciences, Inc. (PCRX) runs a 79.3% gross margin and a 3.3% operating margin, with a 0.7% net margin.
- Where do Pacira BioSciences, Inc.'s ratios come from?
- Every ratio is computed from Pacira BioSciences, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
